FIGURE 7.
Immunoregulatory S100A8/A9 heterodimer induces the accumulation of MDSC in MS patients after glucocorticoid treatment. A, Serum S100A8/A9 heterodimer concentration in serum from MS patients (n = 15) before and after MPPT (MS patients before treatment vs MS patients after treatment, P = 0.0072). B, Levels of S100A8 mRNA were measured by qPCR (MS patients before treatment vs MS patients after treatment, P = 0.0298, n = 5). C, Levels of S100A9 mRNA were measured by qPCR (MS patients before treatment vs MS patients after treatment, P = 0.0814, n = 5). D, Correlation analysis between serum arginase activity and serum S100A8/A9 heterodimer concentration in MS (r 2 = 0.4563, P = 0.0225). E, Levels of Atf3 mRNA were measured by qPCR (MS patients before treatment vs MS patients after treatment, P = 0.7442, n = 5). F, Levels of Irf7 mRNA were measured by qPCR (MS patients before treatment vs MS patients after treatment, P = 0.2035, n = 5)